International Clinical Trial: Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older

Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07734649) titled 'Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older' on July 21.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Triple (Participant, Investigator, Outcomes Assessor).

Primary Sponsor: Sanofi

Condition: Respiratory Syncytial Virus Immunization Human Metapneumovirus Immunization Healthy Volunteers

Intervention: Biological: RSV+HMPV vaccine Biological: Control Vaccine 3 Biological: Control Vaccine 4 Biological: Control Vaccine 2 Other:...